Administration of the FASN inhibitor TVB-2640 for 10 days to obese men with metabolic syndrome suppressed hepatic DNL and reduced hepatic triglyceride content but had no effect on blood glucose, fat oxidation, or plasma triglyceride levels (65). This evidence concerns the gene FASN and metabolic syndrome.